Identification of novel MDR antimicrobials from human microbiome symbioses

从人类微生物组共生体中鉴定新型耐多药抗菌药物

• 批准号: 10592388
• 负责人: NASIA SAFDAR
• 金额: $ 126.61万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10592388
• 关键词: Identification; novel; MDR; antimicrobials; human

Project 3 Project Summary The human body is host to, and interacts with, a complex and dynamic community of microbes called the microbiome. One critical function of the human microbiome is to help protect its host from infection. In project three, we will identify members of the microbiome that can produce antibiotics that are active against drug resistant pathogens and safe for human use. Through the use of genomics, we predict that the human microbiome has the capacity to produce thousands of bioactive natural products that have not been characterized. At UW-Madison, we have several large and ongoing human microbiome studies that provide us access to thousands of samples from diverse populations of people for the isolation and screening of new antimicrobial molecules. We will isolate microbes derived from the human microbiome, determine their antimicrobial activity against Gram-negative and fungal pathogens, and apply our genomics and metabolomics approaches to predict molecules with new chemistry. Our project goals contribute to the mission of the Wisconsin Antimicrobial Drug Discovery and Development Center aiming to develop new therapeutics in response to the growing antimicrobial resistance crisis.

项目3 项目摘要 人体是一个复杂而动态的微生物群落的宿主，并与之相互作用， 微生物组人体微生物组的一个关键功能是帮助保护其宿主免受感染。在 项目三，我们将确定微生物组中可以产生活性抗生素的成员 抗耐药病原体，对人类使用安全。通过使用基因组学，我们预测， 人类微生物组有能力产生数千种具有生物活性的天然产物， 没有被定性。在威斯康星大学麦迪逊分校，我们有几个大型和正在进行的人类微生物组研究 这使我们能够获得来自不同人群的数千个样本，以进行隔离， 筛选新的抗菌分子。我们将从人体微生物组中分离微生物， 确定它们对革兰氏阴性菌和真菌病原体的抗菌活性，并应用我们的 基因组学和代谢组学方法来预测具有新化学的分子。项目目标 为威斯康星州抗菌药物发现和开发中心的使命做出贡献， 开发新的治疗方法，以应对日益严重的抗菌素耐药性危机。